IMD business school for management and leadership courses

In 2022, Bayer announced a $1.4bn investment in digital transformation, emphasizing AI and data science to fuel growth in its pharmaceutical and agricultural sectors. The company is using advanced AI technologies to speed up product development, enhance manufacturing processes, and improve customer delivery. AI also plays a key role in identifying safety issues, ensuring regulatory compliance, optimizing supply chains, reducing operational costs, minimizing waste, and streamlining distribution.

In the consumer health sector, Bayer partnered with Salus Optima to introduce AI-powered health and wellness solutions aimed at promoting healthy aging. Additionally, collaborations with Google Cloud are driving advancements in drug discovery and clinical trials through cutting-edge tools.

Bayer’s Crop Science division is leveraging AI to streamline research and development, reducing research cycles and enabling more sustainable decisions. AI simulations now allow Bayer to predict which genetics, seeds, or germplasm will perform best, reducing the need for in-field testing.

2024 AI-related highlights

• Launches pilot of an expert GenAI system to benefit farmers and agronomists in their daily work (March 2024)
• Partners with Aignostics to develop an AI-powered platform for identifying cancer targets and enhancing oncology clinical development. (Mar 2024)
• Bayer, in partnership with Microsoft, launches GenAI, an AI-driven expert system designed to enhance agriculture efficiency and democratize expert advice for farmers. (Apr 2024)
• Announces partnership with Google to develop AI solutions to support radiologists (April 2024) – Bayer, Daiichi Sankyo, and argenx discuss cautious AI integration in pharma marketing, focusing on real value and patient-centric strategies. (Sept 2024)